[1] Chen S C, Perfect J, Colombo A L, et al.Global guideline for the diagnosis and management of rare yeast infections: aninitiative of the ECMM in cooperation with ISHAM and ASM[J]. Lancet Infect Dis, 2021, 21(12): e375-e386. [2] Kim J, Kim M J, Chong Y P, et al.Comparison of the characteristics of patients with invasive infections andnoninvasive infections caused by Trichosporon asahii[J]. Med Mycol, 2021, 59(3): 296-300. [3] Arendrup M C, Boekhout T, Akova M, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management ofrare invasive yeast infections[J]. Clin Microbiol Infect, 2014, 20 Suppl 3: 76-98. [4] 陈欣, 林韧. 艾沙康唑临床应用专家共识(2023版)[J]. 临床血液学杂志, 2023, 36(05): 295-302. [5] Thompson G R, Wiederhold N P, Sutton D A, et al.In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species[J]. J Antimicrob Chemother, 2009, 64(1): 79-83. [6] Francisco E C, Dieleman C, Hagen F, et al.In vitro activity of isavuconazole against clinically relevant Trichosporonspecies: a comparative evaluation of EUCAST broth microdilution and MIC TestStrip methods[J]. J Antimicrob Chemother, 2023, 78(3): 817-822. [7] 于淑颖, 郭莉娜, 周梦兰, 等. 毛孢子菌研究进展[J]. 中华检验医学杂志, 2018, 41(11): 883-888. [8] Li H, Guo M, Wang C, et al.Epidemiological study of Trichosporon asahii infections over the past 23 years[J]. Epidemiol Infect, 2020, 148: e169. [9] de Almeida J J, Hennequin C. Invasive Trichosporon Infection: a Systematic Review on a Re-emerging FungalPathogen[J]. Front Microbiol, 2016, 7: 1629. [10] Liao Y, Lu X, Yang S, et al. Epidemiology and Outcome of Trichosporon Fungemia: A Review of 185 Reported Cases From1975 to 2014[J]. Open forum infectious diseases, 2015, 2(4): ofv141. [11] Feugray G, Krzisch D, Dehais M, et al.Successful treatment of Trichosporon asahii fungemia with isavuconazole in a patient with hematologic malignancies[J]. Infection and drug resistance, 2019, 12: 2015-2018. [12] Shi C, Xiao Y, Mao Y, et al.Voriconazole: A Review of Population Pharmacokinetic Analyses[J]. Clinical pharmacokinetics, 2019, 58(6): 687-703. [13] Trifilio S M, Scheetz M H, Pi J, et al.Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring[J]. Bone marrow transplantation (Basingstoke), 2010, 45(8): 1352-1356. [14] Vanhove T, Bouwsma H, Hilbrands L, et al.Determinants of the Magnitude of Interaction Between Tacrolimus andVoriconazole/Posaconazole in Solid Organ Recipients[J]. Am J Transplant, 2017, 17(9): 2372-2380. [15] 郭冬杰, 李朋梅, 陈文倩, 等. 伏立康唑对肺移植患者术后他克莫司血药浓度影响的真实世界研究[J]. 中国药房, 2023, 34(20): 2519-2524. [16] Bongomin F, Maguire N, Moore C B, et al.Isavuconazole and voriconazole for the treatment of chronic pulmonaryaspergillosis: A retrospective comparison of rates of adverse events[J]. Mycoses, 2019, 62(3): 217-222. [17] Lewis N J S, Wiederhold N P, Hakki M, et al. New Perspectives on Antimicrobial Agents: Isavuconazole[J]. Antimicrobial agents and chemotherapy, 2022, 66(9): e17722. |